PER® Chemotherapy Foundation Symposium (CFS)

Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection

November 25, 2022

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.

Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung Cancer

November 19, 2022

As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.